Nektar Therapeutics
NKTR
239 hedge funds and large institutions have $2.88B invested in Nektar Therapeutics in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 74 increasing their positions, 79 reducing their positions, and 21 closing their positions.
19% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 21
2% more funds holding
Funds holding: 235 → 239 (+4)
0.07% less ownership
Funds ownership: 6.22% → 6.15% (-0.07%)
5% less call options, than puts
Call options by funds: $11.1M | Put options by funds: $11.8M
6% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 79
15% less capital invested
Capital invested by funds: $3.39B → $2.88B (-$509M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$27.7M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$12.1M |
| 3 |
Millennium Management
New York
|
+$8.64M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.81M |
| 5 |
Two Sigma Investments
New York
|
+$5.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.6M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$30.9M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$16.5M |
| 4 |
BlackRock
New York
|
-$7.95M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$7.63M |
NKTR Hedge Fund Activity: Q2 2021 in Review
239 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2021, worth a combined $2.88B — down 15% from $3.39B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new NKTR positions and 21 closed out — a net gain of 4 holders — while 74 added to existing stakes and 79 trimmed.
The largest buyer was Camber Capital Management, adding an estimated $27.7M. The largest seller was Fidelity Investments, cutting an estimated $36.6M.
- 239 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2021, up from 235 in Q1 2021.
- Funds reported $2.88B of Nektar Therapeutics stock for Q2 2021, down 15% quarter-over-quarter.
- 25 funds opened new Nektar Therapeutics positions in Q2 2021 and 21 closed out, a net change of +4 holders.
- The largest Nektar Therapeutics buyer in Q2 2021 was Camber Capital Management, an estimated $27.7M added.
- The largest Nektar Therapeutics seller in Q2 2021 was Fidelity Investments, an estimated $36.6M sold.
Based on aggregated 13F filings for Q2 2021.